$Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab$

Molecular-based targeted therapies in patients with hepatocellular carcinoma and hepato-cholangiocarcinoma refractory to atezolizumab/bevacizumab

The “French Medicine Genomic program 2025” has been designed to give patients with cancers that are refractory to systemic treatments access to off-label therapies adapted to their specific genomic profile. Herein, we reported the results of this program in patients with advanced hepatocellular carc...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of hepatology 2023-12, Vol.79 (6), p.1450-1458
Hauptverfasser:	Limousin, Wendy, Laurent-Puig, Pierre, Ziol, Marianne, Ganne-Carrié, Nathalie, Nahon, Pierre, Ait-Omar, Amal, Seror, Olivier, Sidali, Sabrina, Campani, Claudia, Blanc, Pierre, Lermine, Alban, Marisa, Laetitia, Zucman-Rossi, Jessica, Nault, Jean-Charles
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Bevacizumab - therapeutic use Bile Duct Neoplasms - drug therapy Bile Duct Neoplasms - genetics Bile Ducts, Intrahepatic Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - genetics Cholangiocarcinoma - drug therapy Cholangiocarcinoma - genetics Everolimus Female hepatocellular carcinoma hepatocholangiocarcinoma Humans Liver Neoplasms - drug therapy Liver Neoplasms - genetics Male Middle Aged Molecular Targeted Therapy next generation sequencing Pilot Projects Precision Medicine targeted therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!